Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA 1265 is a small, non-coding RNA molecule belonging to the miRNA class. It is transcribed as a primary miRNA (~70 nucleotides), processed to a mature form (20-24 nucleotides), and incorporated into the RNA-induced silencing complex (RISC), where it binds target mRNAs through imperfect base pairing to regulate gene expression by translational inhibition or destabilization of the mRNA. Its specific biological targets and regulatory roles are currently uncharacterized, but, like other microRNAs, it modulates gene expression post-transcriptionally in multicellular organisms. MIR1265 has been weakly linked by association to Juvenile Myoclonic Epilepsy, but no mechanistic studies or clinical applications have been established[1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MicroRNA 1265 (MIR1265).